Abstract: Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed insulin isoform or C? polypeptide are provided. Methods of detecting insulin isoforms or C? polypeptides are also provided.

Abstract: A circuit includes: a power generation module a low-frequency motion energy harvesting module, configured to harvest a direct current output by the power generation module when the human body is in a low-frequency motion state; a high-frequency motion energy harvesting module, configured to harvest a direct current output by the power generation module when the human body is in a high-frequency motion state; an energyrespectively connected to the low frequency motion cncrgy harvesting modulo configured to store electrical energy; and a motion switching module, respectively connected to the power generation module, the low-frequency motion energy harvesting module and the high-frequency motion energy harvesting module, and configured to monitor a human body motion state, and control, according to the human body motion state, switching between operation of the low-frequency motion energy harvesting module and operation of the high-frequency motion energy harvesting module, to respectively charge the energy stor

Abstract: The present invention provides a transgenic mouse and an animal model that is used to assay for the inhibition or activation of the Cnr2 gene and methods for screening drugs to treat or prevent psychosis, anxiety, depression, autism disorders, drug addiction, Parkinson's disease and/or Alzheimer's disease, multiple sclerosis, inflammation, stroke, osteoporosis, scleroderma or cancer.

Abstract: An emulsion composition comprising at least: (a) an oil phase; (b) a polyol; and (c) an amphoteric surfactant. Preferably, the emulsion composition is substantially free or completely free of any nonionic surfactant. The emulsion composition has excellent stability.

Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.